全文获取类型
收费全文 | 128284篇 |
免费 | 13497篇 |
国内免费 | 4508篇 |
专业分类
耳鼻咽喉 | 995篇 |
儿科学 | 1870篇 |
妇产科学 | 1648篇 |
基础医学 | 24748篇 |
口腔科学 | 3241篇 |
临床医学 | 7809篇 |
内科学 | 18095篇 |
皮肤病学 | 2408篇 |
神经病学 | 12423篇 |
特种医学 | 3218篇 |
外国民族医学 | 40篇 |
外科学 | 9795篇 |
综合类 | 14329篇 |
现状与发展 | 20篇 |
预防医学 | 4783篇 |
眼科学 | 1284篇 |
药学 | 19174篇 |
36篇 | |
中国医学 | 4533篇 |
肿瘤学 | 15840篇 |
出版年
2024年 | 156篇 |
2023年 | 2054篇 |
2022年 | 2830篇 |
2021年 | 5607篇 |
2020年 | 4806篇 |
2019年 | 4923篇 |
2018年 | 4687篇 |
2017年 | 4786篇 |
2016年 | 4592篇 |
2015年 | 5389篇 |
2014年 | 7664篇 |
2013年 | 7941篇 |
2012年 | 7054篇 |
2011年 | 8527篇 |
2010年 | 6923篇 |
2009年 | 7042篇 |
2008年 | 6986篇 |
2007年 | 6212篇 |
2006年 | 5399篇 |
2005年 | 5043篇 |
2004年 | 4401篇 |
2003年 | 4006篇 |
2002年 | 3163篇 |
2001年 | 2771篇 |
2000年 | 2392篇 |
1999年 | 2109篇 |
1998年 | 1965篇 |
1997年 | 1845篇 |
1996年 | 1332篇 |
1995年 | 1450篇 |
1994年 | 1228篇 |
1993年 | 1127篇 |
1992年 | 860篇 |
1991年 | 765篇 |
1990年 | 632篇 |
1989年 | 546篇 |
1988年 | 534篇 |
1987年 | 511篇 |
1986年 | 613篇 |
1985年 | 833篇 |
1984年 | 796篇 |
1983年 | 603篇 |
1982年 | 619篇 |
1981年 | 525篇 |
1980年 | 486篇 |
1979年 | 403篇 |
1978年 | 255篇 |
1977年 | 215篇 |
1976年 | 217篇 |
1975年 | 136篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
目的 收集藿香正气汤的主要活性成分,通过分子对接及网络药理学探讨其防控新型冠状病毒肺炎(COVID-19)的有效成分及治疗机制。方法 通过基于配体-蛋白质相互作用的计算方法,以瑞德西韦为对照,探索藿香正气汤潜在治疗COVID-19的成分,并选出对接较好成分进行药理学机制预测,初探其药理学机制。结果 本研究筛选出5种与新冠病毒3CLpro结合能力强于瑞德西韦的小分子成分。网络药理学初步预测抗病毒途径可能是通过PI3K-Akt 信号通路影响病毒复制。结论 成分C1-C5与3CLpro结合良好,推测其可能是潜在的3CLpro的抑制剂,为抗病毒天然药物的开发提供了理论依据。 相似文献
42.
目的:研究PTPN6对前列腺癌细胞PC3的作用及其作用机制。方法:RT-PCR和Western blot实验检测前列腺癌组织和细胞以及癌旁组织和人前列腺上皮细胞中PTPN6的表达量;CCK-8和EDU染色实验检测PTPN6对前列腺癌细胞PC3增殖的影响;Western blot实验检测耐药相关蛋白P-gp和MRP-1的蛋白表达水平。结果:RT-PCR和Western blot结果显示,PTPN6在前列腺癌组织和细胞中的表达量显著低于癌旁组织和人前列腺上皮细胞中的表达量;过表达PTPN6显著抑制前列腺癌PC3细胞的增殖,并降低PC3细胞的耐药性;进一步的研究结果表明PTPN6可通过抑制SP1,并抑制p38 MAPK通路抑制PC3细胞的增殖和耐药。结论:PTPN6能够抑制前列腺癌细胞PC3的增殖和耐药,提高其化疗敏感性,作用机制是通过调控SP1/p38 MAPK信号通路来实现的,这一结果能够为临床上前列腺癌的诊断和治疗提供分子基础。 相似文献
43.
44.
45.
46.
J. Savige L. Amos Frank Ierino H. G. Mack R. C. Andrew Symons P. Hughes 《Ophthalmic genetics》2016,37(4):369-376
Background: Dense deposit disease and atypical hemolytic uremic syndrome are often caused by Complement Factor H (CFH) mutations. This study describes the retinal abnormalities in dense deposit disease and, for the first time, atypical haemolytic uremic syndrome. It also reviews our understanding of drusen pathogenesis and their relevance for glomerular disease. Methods: Six individuals with dense deposit disease and one with atypical haemolytic uremic syndrome were studied from 2 to 40 years after presentation. Five had renal transplants. All four who had genetic testing had CFH mutations. Individuals underwent ophthalmological review and retinal photography, and in some cases, optical coherence tomography, and further tests of retinal function. Results: All subjects with dense deposit disease had impaired night vision and retinal drusen or whitish-yellow deposits. Retinal atrophy, pigmentation, and hemorrhage were common. In late disease, peripheral vision was restricted, central vision was distorted, and there were scotoma from sub-retinal choroidal neovascular membranes and atypical serous retinopathy. Drusen were present but less prominent in the young person with atypical uremic syndrome due to a heterozygous CFH mutation. Conclusions: Drusen are common in forms of C3 glomerulopathy caused by compound heterozygous or heterozygous CFH mutations. They are useful diagnostically but also impair vision. Drusen have an identical composition to glomerular deposits. They are also identical to the drusen of age-related macular degeneration, and may respond to the same treatments. Individuals with a C3 glomerulopathy should be assessed ophthalmologically at diagnosis, and monitored regularly for vision-threatening complications. 相似文献
47.
48.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
49.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
50.
《The Journal for Nurse Practitioners》2022,18(5):503-505
This article begins with an overview of the knowledge translation (KT) process, introduces commonly used KT terms and the Aware-Adopt-Adapt (A3) KT map. The A3 was created by a nurse practitioner (NP) for practitioners and NP students to provide a map for those who wish to move existing knowledge to practice, yet do not know where to start or do not have the time to take a deeper dive into specific KT theories. 相似文献